Loading
A phase 2 trial of Ciltacabtagene autoleucel, Talquetamab in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma is a phase 2 interventional study registered as NCT06550895 by Janssen Research & Development, LLC, with 11 participants enrolled, started 2024-09-16 and due to reach its primary completion in 2027-08-26. Interventions recorded: Cilta-cel, Talquetamab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Talquetamab, Ciltacabtagene autoleucel, Johnson & Johnson, T-cell engagers (bispecific).
Shares Ciltacabtagene autoleucel, Johnson & Johnson, CAR-T cell therapy, Multiple myeloma.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Ciltacabtagene autoleucel, Johnson & Johnson, Multiple myeloma.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/